Skip to main navigation Skip to search Skip to main content

Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients

  • Henrike Westerveld*
  • , Astrid de Leeuw
  • , EMBRACE Collaborative Group
  • , Kathrin Kirchheiner
  • , Pittaya Dankulchai
  • , Bernard Oosterveld
  • , Arun Oinam
  • , Robert Hudej
  • , Jamema Swamidas
  • , Jacob Lindegaard
  • , Kari Tanderup
  • , Richard Pötter
  • , Christian Kirisits
  • *Corresponding author for this work
  • Amsterdam UMC
  • University Medical Centre Utrecht
  • Medical University of Vienna
  • Mahidol University
  • Department of Radiation Oncology
  • Postgraduate Institute of Medical Education and Research
  • Institute of Oncology Ljubljana
  • Tata Memorial Hospital
  • Aarhus University Hospital

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: 

Recently, a vaginal dose reporting method for combined EBRT and BT in cervical cancer patients was proposed. The current study was to evaluate vaginal doses with this method in a multicentre setting, wherein different applicators, dose rates and protocols were used.

MATERIAL AND METHODS: 

In a subset of patients from the EMBRACE study, vaginal doses were evaluated. Doses at the applicator surface left/right and anterior/posterior and at 5mm depth were measured. In addition, the dose at the Posterior-Inferior Border of Symphysis (PIBS) vaginal dose point and PIBS±2cm, corresponding to the mid and lower vagina, was measured.

RESULTS: 

153 patients from seven institutions were included. Large dose variations expressed in EQD2 with α/β=3Gy were seen between patients, in particular at the top left and right vaginal wall (median 195 (range 61-947)Gy/178 (61-980)Gy, respectively). At 5mm depth, doses were 98 (55-212)Gy/91 (54-227)Gy left/right, and 71 (51-145)Gy/67 (49-189)Gy anterior/posterior, respectively. The dose at PIBS and PIBS±2cm was 41 (3-81)Gy, 54 (32-109)Gy and 5 (1-51)Gy, respectively. At PIBS+2cm (mid vagina) dose variation was coming from BT. The variation at PIBS-2cm (lower vagina) was mainly dependent on EBRT field border location.

CONCLUSIONS: 

This novel method for reporting vaginal doses coming from EBRT and BT through well-defined dose points gives a robust representation of the dose along the vaginal axis. In addition, it allows comparison of vaginal dose between patients from different centres. The doses at the PIBS points represent the doses at the mid and lower parts of the vagina. Large variations in dose throughout the vagina were observed between patients and centres.

Original languageEnglish
Pages (from-to)420-427
Number of pages8
JournalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume120
Issue number3
DOIs
Publication statusPublished - Sept 2016
Externally publishedYes

Bibliographical note

Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients'. Together they form a unique fingerprint.

Cite this